Published in

Taylor and Francis Group, OncoImmunology, 9(1), p. 1617-1619

DOI: 10.4161/onci.21513

Links

Tools

Export citation

Search in Google Scholar

Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?

Journal article published in 2012 by Yann Godet, Magalie Dosset ORCID, Christophe Borg, Olivier Adotevi
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Insights into antitumor T-cell responses may help the development of more efficient treatments for lung cancer. The interplay between preexisting antitumor CD4(+) T-cell responses and platinum-based chemotherapy is crucial to improve patient survival. Accumulating evidence confirms that selecting cancer patients in whom chemotherapy can activate an anticancer immune response would largely improve the success of novel therapeutic approaches.